Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complications of Diabetes Mellitus01:22

Complications of Diabetes Mellitus

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to insulin deficiency, resistance, or both. Prolonged hyperglycemia disrupts metabolic homeostasis and leads to acute and chronic complications.Acute ComplicationsAcute complications result from sudden metabolic imbalance.Diabetic ketoacidosis (DKA) mainly appears in type 1 diabetes but may also develop in type 2 diabetes, particularly under extreme stress. It arises from severe insulin deficiency,...
Hyperosmolar Hyperglycemic State01:21

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hydroxyurea interferes with point-of-care creatinine testing in children with sickle cell anemia.

BMC research notes·2026
Same author

Ten Years of Hydroxyurea for Ugandan Children with Sickle Cell Anemia.

The New England journal of medicine·2026
Same author

Persistent Splenomegaly Is Associated with Morbidity in Tanzanian Children with Sickle Cell Anemia: Secondary Analysis of the SPHERE Trial.

Acta haematologica·2026
Same author

Growth and puberty in African children with sickle cell anemia treated with hydroxyurea.

Blood advances·2026
Same author

Sickle Cell Disease in Sub-Saharan Africa: Progress and Potential.

American journal of hematology·2026
Same author

Newborn screening results for sickle cell disease from the ASH Consortium on Newborn Screening in Africa (CONSA).

Blood advances·2026
Same journal

Integrating intraspecific trait variation and spatiotemporal variability of selection as levers of action in forest management.

Comptes rendus biologies·2026
Same journal

[Managing mixed forest stands : bridging the gap between silviculture and ecological theory].

Comptes rendus biologies·2026
Same journal

[Which forests for which biodiversity under climate change?]

Comptes rendus biologies·2026
Same journal

[Impacts of climate change on the functioning and productivity of agroecosystems: a focus on the impact of interactions between CO<sub>2</sub>, temperature and water deficit].

Comptes rendus biologies·2026
Same journal

Autogenic transitions in individuality.

Comptes rendus biologies·2026
Same journal

Assessing the potential effects of climate change on future forest composition in France.

Comptes rendus biologies·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides (CHIPS)
06:34

Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides (CHIPS)

Published on: June 20, 2014

Hydroxycarbamide: clinical aspects.

Russell E Ware1

  • 1Center for Global Health, Baylor College of Medicine and Texas Children's Hospital, 1102 Bates Street, Houston, TX 77030, USA. reware@bcm.edu

Comptes Rendus Biologies
|May 7, 2013
PubMed
Summary
This summary is machine-generated.

Hydroxyurea is an effective oral treatment for children with sickle cell anemia (SCA), increasing fetal hemoglobin (HbF) and reducing complications. Long-term studies show no increased risks, making it a safe option for most SCA patients.

Related Experiment Videos

Last Updated: May 11, 2026

Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides (CHIPS)
06:34

Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides (CHIPS)

Published on: June 20, 2014

Area of Science:

  • Hematology
  • Pediatric Medicine
  • Pharmacology

Background:

  • Sickle cell anemia (SCA) is a serious genetic blood disorder.
  • Current treatments for SCA have limitations.
  • Fetal hemoglobin (HbF) induction is a key therapeutic strategy.

Purpose of the Study:

  • To evaluate hydroxyurea as a primary treatment for inducing fetal hemoglobin (HbF) in children with SCA.
  • To assess the efficacy and safety of long-term hydroxyurea use in SCA patients.

Main Methods:

  • Oral administration of hydroxyurea once daily.
  • Monitoring of laboratory markers including hemoglobin (Hb) and HbF levels.
  • Tracking clinical outcomes such as painful episodes, acute chest syndrome, transfusions, and hospitalizations.
  • Assessing maximum tolerated dose and potential toxicities.

Main Results:

  • Hydroxyurea significantly increases Hb and HbF levels.
  • Treatment leads to reduced painful episodes, acute chest syndrome, transfusions, and hospitalizations.
  • Most patients achieve therapeutic goals at doses of 25-30 mg/kg/d without excessive myelosuppression.
  • Long-term follow-up (up to 15 years) has not revealed increased risks of stroke, myelodysplasia, or carcinogenicity.

Conclusions:

  • Hydroxyurea is an inexpensive, effective, and well-tolerated disease-modifying therapy for SCA.
  • It is recommended for most, if not all, SCA patients, including in resource-limited settings.
  • Emerging evidence supports hydroxyurea as a safe and effective treatment for SCA in both developed and developing countries.